|
 |
 Home > Available Issues |
|
|
 Original Articles |
| Activities of fluconazole, amphotericin B and 5-fluorocytosine against Candida albicans and Cryptococcus neoformans isolates |
| Yunsop Chong, Samuel Y. Lee |
| Department of Clinical Pathology, Yonsei University College of Medicine, Seoul, Korea |
Vol.22 Num.3 (p147~150)
|
|
|
Serious Candia albicans infection is now well recognized problem among the compromised patients. Cryptococcus neoformans meningitis, a rare disease previously, became more frequently encountered. For the treatment of fungal infections not many agents were available. In this study, activities of fluconazole, amphotericin B and 5-fluorocytosine against clinical isolates of C. albicans and C. neoformans were tested by the agar dilution test using high resolution medium. Against C. albicans, the MIC range of fluconazole was 0.4~12.5 μg/mL. MIC50 and MIC90 were 1.6 μg/mL and 3.1 μg/mL, respectively. The MIC range of amphotericin B was 0.2~.8 μg/mL. MIC range of 5-fluorocytosine was 0.4->100 μg/mL and MIC50 and MIC90 were 1.6 and >100 μg/mL, respectively. Against C. neoformans, MIC range of fluconazole was 3.1~50 μg/mL. Both MIC50 and MIC90 were 50 μg/mL. Growth of all isolates were inhibited by 0.4 μg/mL of amphotericin B. MIC range of 5-fluorocytosine was 25->100 μg/mL and both MIC50 and MIC90 were 50 μg/mL. Although in vitro test results of fluconazole seldome predicts in vivo efficacy, by comparing our in vitro data to those of others, who did both in vitro test and clinical trials, it was concluded that fluconazole could be effectively used for the treatment of most of the C. albicans and C. neoformans infections in Korea.
|
|
|
Keywords : |
|
|
|
|
|
|
|
|
